Turning peptides into drugs
It is possible to overcome most of the challenges of using peptides as drugs through peptide enhancement techniques. These aims to constrain the structure of the amino acid chain to make it more rigid and stable, thereby decreasing its susceptibility to degradation, all while maintaining or improving the efficacy of the molecule.
Through Zealand’s 13 years of experience, the company has been focused on peptide drug discovery and development and built a world-leading position in the field. We have an experienced and integrated R&D organization, broadly recognized for its capabilities, and with all main functions in-house, including:
- Identification of novel biological targets and testing of their therapeutic relevance (idea generation)
- Innovation, design, modification and optimization of peptides
- Solutions to the challenges of turning peptide molecules into durable, stable and cost-effective drugs
- Preclinical and clinical development of novel drugs targeting diabetes/metabolic diseases and related disorders
Through our focused R&D process and our skills in peptide drug innovation and optimization we have created focused peptide libraries consisting of more than 3,900 peptides, filed 440 active patent applications, of which 159 have been issued, and have taken 8 new compounds into the clinic since our interception in 1998.
An example of a Zealand proprietary peptide enhancing technology is the SIP® tail technology, which stands for Structure Induced Probe. The SIP® technology adds a number of specific aminoacids to the peptide, thereby strengthening or tightening its molecular structure to make it less susceptible to biological degradation. This ensures a longer life-span in the blood and thereby
permits less frequent dosing. The SIP® technology has been employed for lixisenatide, ZP1846 and elsiglutide.
More recent projects at Zealand have involved the addition of a fatty acid to the amino acid chain of a given peptide as another technique to increase its half life in the blood stream, working with dual acting peptides where one compound is able to simultaneously activate two different
peptide receptors (e.g. ZP2929), and the use of new methods to restrain the peptide structure as in the collaboration with Pepscan.